RxDoctor Payments Data

Marcia Green, NP

Family · Chapin, SCNPI 1033651500

Payments from drug & device makers

$734in general payments, 2019–2025

Across 29 payments — averaging $25.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sun Pharmaceutical Industries Inc.$210
  • Neurocrine Biosciences, Inc.$111
  • Acadia Pharmaceuticals Inc$109
  • Mylan Specialty L.p.$84
  • Teva Pharmaceuticals USA, Inc.$80
  • Lilly USA, LLC$45
  • plus $96 from 5 others

What the payments were for

  • Food & beverage$734100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$734 in reported general payments places this provider in the 60th percentile of 3,248 family providers in South Carolina.

See all family providers in South Carolina

Medicare billing

Part B allowed, 2024
$154,444
Medicare patients
139
Services billed
1,725

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
YupelriRevefenacin60$54,397
EliquisApixaban80$28,859
TrulicityDulaglutide16$14,428
Pantoprazole Sodium59$6,533
MyrbetriqMirabegron26$6,015
Divalproex Sodium122$5,881
JardianceEmpagliflozin12$5,841
XareltoRivaroxaban11$3,320
Mirtazapine83$2,990
Hydroxyzine Hcl76$2,584
Metformin Hcl47$2,413
Ondansetron OdtOndansetron38$1,823
Trazodone Hcl152$1,752
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog11$1,517
Buspirone Hcl80$1,300

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Mylan Specialty L.p.Yupelri$84$54,39760 claims
Lilly USA, LLCTrulicity, Olanzapine$45$15,14154 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 3,248 family providers in South Carolina.

Other family in Chapin

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →